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2560Objective:Apolipoprotein E (APOE) genotype is a determinant of neurologic recovery after brain ischemia and
traumatic brain injury. The APOE ε2 allele has been associated with worse neurodevelopmental (ND) outcome
after repair of congenital heart defects (CHD) in infancy. Replication of this finding in an independent cohort is
essential to validate the observed genotype-phenotype association.
Methods: The association of APOE genotype with ND outcomes was assessed in a combined cohort of patients
with single-ventricle CHD enrolled in the Single Ventricle Reconstruction and Infant Single Ventricle trials. ND
outcome was assessed at 14 months using the Psychomotor Development Index (PDI) and Mental Development
Index (MDI) of the Bayley Scales of Infant Development-II. Stepwise multivariable regression was performed to
develop predictive models for PDI and MDI scores.
Results: Complete data were available for 298 of 435 patients. After adjustment for preoperative and postop-
erative covariates, the APOE ε2 allele was associated with a lower PDI score (P ¼ .038). Patients with the ε2
allele had a PDI score approximately 6 points lower than those without the risk allele, explaining 1.04% of over-
all PDI variance, because the ε2 allele was present in only 11% of the patients. Therewas a marginal effect of the
ε2 allele on MDI scores (P ¼ .058).
Conclusions: These data validate the association of the APOE ε2 allele with adverse early ND outcomes after
cardiac surgery in infants, independent of patient and operative factors. Genetic variants that decrease neurore-
silience and impair neuronal repair after brain injury are important risk factors for ND dysfunction after surgery
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DA dramatic reduction in mortality after surgical correction of
congenital heart defects (CHD) in recent years has been
accompaniedby increasing recognitionof adverseneurodeve-
lopmental (ND) outcomes in some survivors.1 Evaluation of
children after neonatal repair of CHD demonstrates a pattern
of ND sequelae characterized by cognitive impairment,
speech and language abnormalities, impaired visual-spatial
and visual-motor skills, attention deficit hyperactivity disor-
der, motor delays, and learning disabilities.2-4
Cerebral ischemia in the perioperative period has been
proposed as a primarymechanism of central nervous system
(CNS) injury. Management strategies during the operation,
including type of support (deep hypothermic circulatory
arrest [DHCA] or continuous cardiopulmonary bypass
[CPB]), hemodilution, degree of cooling, and blood gas
management, have been implicated as factors in postopera-
tive ND dysfunction. These potential risk factors do not
fully explain the frequency or pattern of ND dysfunc-
tion.5-8 There is significant interindividual variation in
developmental outcome, even among children with the
same cardiac defect, suggesting that other patient-specific
factors may be important determinants of CNS injury.6
Genetic polymorphisms that increase susceptibility to
neurologic injury are potentially important modifiers of
ND outcome in children with CHD. Apolipoprotein
E (APOE) genotype has been shown to have an important
role as a determinant of neurologic recovery after CNS
ischemia, intracerebral hemorrhage, and traumatic brain
injury.9 A previous study demonstrated an associationThe Journal of Thoracic and Carbetween the APOE ε2 allele and postoperative ND disabil-
ities in neonates and infants undergoing cardiac surgery
with CPB.10 In that study, early ND outcomes were assessed
with the Bayley Scales of Infant Development-II (BSID-II).
Most initial reports of genotype-phenotype associations
are not subsequently validated. Ideally, validation should
be performed in a similar population with similar environ-
mental exposures. The phenotype assessed in the validation
study should be the same as the initial report and similar
measures used. In the current study, a combined cohort of
patients from the Infant Single Ventricle (ISV) and Single
Ventricle Reconstruction (SVR) trials was used to validate
the association of the APOE ε2 allele with ND outcomes
after surgery for CHD in infancy. For both the ISV and
SVR trials, the study population consisted of infants with
single-ventricle CHD who underwent surgery in the first
year of life and in whom an ND evaluation was performed
at 14 months of age using the BSID-II.7,8,11-13
METHODS
Study Population
The study population includes patients from both the ISVand SVR trials
performed by the Pediatric Heart Network (PHN). The inclusion and exclu-
sion criteria, studydesigns, and theparticipating centers for both studies have
been described previously.12,13 The study populations contain many
similarities that justify their grouping for the current study. In brief,
inclusion criteria for the ISV study included (1) single-ventricle–type
CHD (except pulmonary atresia with intact ventricular septum),
(2) planned superior vena caval to pulmonary artery connection, and
(3) absence of a genetic or medical condition that would affect
growth. Inclusion criteria for the SVR trial included (1) a diagnosis of
hypoplastic left heart syndrome (HLHS) or a related single, morphologic,
right ventricular anomaly, (2) planned Norwood procedure, and (3)
absence of a genetic or medical condition that would affect transplant-free
survival. The primary outcomes and ND outcomes for both studies have
been published previously.7,8,13 For the ISV trial, DNAwas extracted from
peripheral blood samples and testing of renin-angiotensin-aldosterone sys-
tem pathway variants was performed.14 DNA samples were stored for future
testing in the PHN biorepository in accordance with the informed consent
process. Samples were sent to the University of Michigan for APOE geno-
typing. Participants in the ISV study who did not consent to future testing
of their samples were not included in the current study. For the SVR trial,
the participants gave consent forAPOE genotyping. Sampleswere identified
by the PHN Data Coordinating Center to verify that participants who were
enrolled in both studies were only represented once in the current study.
Genotyping
Two methods were used to establish APOE genotype. The ε2 allele
consists of a cysteine at positions 112 and 158; ε3 consists of a cysteine
at position 112 and an arginine at position 158; ε4 consists of an arginine
at both positions. These alleles result in 6 possible genotypes: 3 homozy-
gous genotypes (ε2/ε2, ε3/ε3, and ε4/ε4) and 3 heterozygous genotypes
(ε2/ε3, ε2/ε4, and ε3/ε4).
For the SVR participants, buccal swab epithelial cells were collected
using CytoSoft cytology brushes (Medical Packaging Corporation, Cama-
rillo, Calif) after obtaining informed consent. Genomic DNAwas extracted
using a PureGene kit (Gentra Systems, Inc,Minneapolis,Minn) according to
themanufacturer’s protocol. Genotype analysis for the presence of the single
nucleotide polymorphisms that specify a cysteine and/or an arginine residue
at codons 112 and 158 of the APOE gene, which define the ε2, ε3, and ε4diovascular Surgery c Volume 148, Number 6 2561
Congenital Heart Disease Gaynor et al
C
H
Dalleles, was performed using a TaqMan assay and an ABI Prism 7000
Sequence Detection System (Applied Biosystems, Foster City, Calif) as
described by Koch and colleagues.15 Reactions were carried out in 96-well
microtiter plates in the ABI Prism 7000 Sequence Detection System. The
assay volume of 22 mL consisted of 11 mL of 23 TaqMan Universal PCR
Master Mix (Applied Biosystems), 75 nmol/L each forward and reverse
primers, 25 nmol/L each allele specific probe, and 2 mL of DNA (30-100
ng). Amplification involved 40 cycles of denaturation at 95C for 15 seconds
and primer annealing and extension at 60C for 1 minute. Patient samples
were run along with controls representing all 3 possible genotypes (ie,
Cys/Cys, Cys/Arg, and Arg/Arg) as well as a no-template control. Postam-
plification analysis of the genotypes at each codon was performed using
the allelic discrimination analysis module of the ABI 7000 Sequence Detec-
tion System. The genotype of the patientwas deduced from the combined re-
sults at amino acid positions 112 and 158. DNA samples were available for
398 SVR participants and genotyping was successful for 397. However, for
90 samples, there was no consent to use the DNA for secondary studies.
The ISV samples were amplified by polymerase chain reaction (PCR)
and the amplicons were subjected to Sanger sequencing. PCR primers
were designed to produce an amplicon containing the sequence differences
that are associatedwith theAPOE ε2, ε3, and ε4 variants. PCRprimerswere
selected using the LaserGene Primer Select Program (DNASTAR Inc,Mad-
ison, Wis). Forward (50-CCG CCC CAT CCC AGC CCT TCT CC) and
reverse (50-TCC GGC TGC CCA TCT CCT CCA TCC) primers were
selected. A 12-mL PCR reaction was set up for each patient and control
DNA sample. Each 12-mL PCR reaction contained 1 mL of 10-40 ng
genomic patient or control DNA, 1 mL of 1.5 pmol forward primer, 1 mL
of 1.5 pmol reverse primer, 3 mL of DNase/RNase free water, and 6 mL of
HotStarTaq polymerase mixture (Qiagen, Inc, Valencia, Calif). PCR DNA
amplification was performed on a thermal cycler (Bio-Rad MyCycler,
Bio-Rad Life Sciences, Hercules, Calif) using 96-well plates. A touchdown
PCR protocol was used as follows: initial denaturation at 94C for 15 min-
utes, followed by 24 cycleswith an annealing temperature decreasing 0.7C
per cycle, starting at 72C for 30 seconds; denaturation at 94C for 30 sec-
onds, and extension at 72C for 1 minute. An additional 32 cycles were
added: 94C for 30 seconds, 55C for 30 seconds, 72C for 1 minute,
with a final extension of 72C for 10minutes. Each PCRproductwas diluted
with 40 mL of distilled water and submitted for sequencing. Sanger
sequencingwas performed by theUniversity ofMichiganDNASequencing
Core facility using an Applied Biosystems DNA Sequencer (Model 3730
XL). Each chromatogramwas visually inspected usingAppliedBiosystems
Sequence Scanner (v1.0) software to determine genotypes. Twenty-eight
samplesweregenotyped using bothmethodswith 100% concordance of ge-
notypeswith all genotype combinations represented. DNAwas available for
160 patients and adequate genotypeswere obtained in 150. Genotyping was
unsuccessful in 10 patients because of low sample quantity or quality.FIGURE 1. The study cohort. ISV, Infant Single Ventricle trial;
SVR, Single Ventricle Reconstruction trial; APOE, apolipoprotein E.Neurodevelopmental Evaluation
In both trials, ND testingwith the BSID-II was performed at 14months by
a designated study-site psychologist certified by the PHN’s neuropsycholog-
ical testing consultant (DCB). The BSID-II was administered in English or
Spanish depending on the dominant language spoken at home. The BSID-II
offers a standardized assessment of cognitive andmotor development for chil-
dren aged 1 to 42months.16 It yields 2 scores: the Psychomotor Development
Index (PDI) and theMentalDevelopment Index (MDI).ThePDI assesses con-
trol of gross muscle function, including crawling and walking, as well as fine
muscle skills necessary for prehension, use of writing instruments, and imita-
tion of hand movements. The MDI assesses memory, problem solving,
early number concepts, generalization, vocalizations, and language and social
skills. Themean standard deviation is 100 15 in the normative population
for both scores. Patients who were too impaired to complete neurodevelop-
mental testing were assigned a score of 50. The PDI score is usually
more severely affected in infant survivors of cardiac surgery than the MDI
score.5,72562 The Journal of Thoracic and Cardiovascular SurStatistical Analyses
All analyses were performed in R (http://www.r-project.org/). APOE
genotypes were classified into 3 groups as follows: ε2 (ε2ε2 or ε2ε3), ε3
(ε3ε3), or ε4 (ε4ε3 or ε4ε4). Participants with ε2ε4 genotype (n ¼ 9)
were excluded from the analyses because the alleles have opposing effects
in adults and cannot be placed in either the ε2 or ε4 groups. Stepwise linear
regression analysis was used to select from the numerous demographic,
clinical, and genetic variables entering the model those that have the great-
est contribution to the model as measured by Akaike’s information crite-
rion (AIC). The variables included in the stepwise regression model were
surgical center, gender, a dummy variable for race with the white subgroup
(the majority racial group) as the reference group, HLHS, gestational age,
birth weight, presence of a genetic anomaly, post-Norwood length of stay
(LOS) or LOS after neonatal palliative surgery, bypass time during pallia-
tive surgery, aortic crossclamp time, DHCA time, weight at stage 2 surgery,
height at stage 2 surgery, head circumference at stage 2 surgery, post-stage
2 surgery LOS, weight/height/head circumference at 14 months, maternal
education, and number of serious adverse events until 14 months of age.
Model comparison was performed using AIC, beginning with a base model
that included only surgical site and presence of genetic syndrome. Only
specific demographic, clinical, and genetic variables that improved model
prediction of the outcome of either MDI or PDI at 14 months were retained
in each respective final regression model. A subgroup analysis was per-
formed for nonsyndromic participants (n ¼ 232) to ensure that APOE ε2
genotype effects were consistent when excluding participants with chro-
mosomal or other genetic anomalies.RESULTS
The ISV trial randomized 230 patients. The SVR trial
randomized 549 patients. There were 66 patients enrolled
in both studies resulting in 713 unique participants for the
combined cohort. There was no overlap with the original
discovery cohort. In the ISV trial, 92% of survivors re-
turned and had valid BSID-II scores.8 In the SVR trial,
the follow-up rate for the BSID-II examination among
transplant-free survivors was 86%.7 Overall, the ND evalu-
ation was completed in 435 patients. Complete data,
including APOE genotype, were available for 298 patients,
who form the study cohort (Figure 1). The most commongery c December 2014
TABLE 1. Comparison between patients with complete and incomplete data
Complete data (n ¼ 298) Incomplete data (n ¼ 137) P value
Patient variables
Gender, n (%)
Male 193 (64.8) 85 (62.0) .59
Female 105 (35.2) 52 (38.0)
Race/ethnicity, n (%)
White 196 (65.8) 104 (75.9) .035
Black 25 (8.4) 24 (17.5) .084
Hispanic 64 (21.5) 9 (6.6) 5.32 3 105
Other 13 (4.3) 0 .012
Hypoplastic left heart syndrome, n (%) 230 (77.2) 112 (81.8) .32
Gestational age, wk  SD 38.3  1.49 38.4  1.38 .52
Birth weight, kg  SD 3.198  0.516 3.162  0.527 .51
Genetic or chromosomal syndrome, n (%) 47 (15.8) 31 (22.6) .11
Maternal education, n (%)*
Elementary school 8 (2.7) 1 (0.9) .14
Junior high 4 (1.3) 1 (0.9)
Some high school 23 (7.7) 8 (6.7)
High school or GED equivalent 46 (15.4) 33 (27.7)
Some college or 2-y vocational school 95 (31.9) 35 (29.4)
4-y college 84 (28.2) 30 (25.2)
Graduate degree 38 (12.8) 11 (9.2)
APOE genotype
ε2 (ε2/ε3 or ε2/ε2) 33 (11.1)
ε3 (ε3/ε3) 178 (59.7)
ε4 (ε3/ε4 or ε4/ε4) 87 (29.2)
ε2/ε4 0 9 (6.6)
Stage 1
Cardiopulmonary bypass time, min  SD 130.4  53.4 139.1  51.4 .11
Crossclamp time, min  SD 49.85  25.1 53.6  24.5 .15
DHCA use, n (%) 255 (85.6) 121 (88.3) .45
Post-Norwood procedure LOS, d  SD 30.8  30.4 31.9  29.3 .73
Stage 2
Pre-stage 2 weight, kg  SD 5.89  1.07 5.92  1.04 .79
Pre-stage 2 height, cm  SD 61.6  4.30 62.03  4.24 .34
Pre-stage 2 head circumference, cm  SD 39.9  2.34 40.3  2.20 .10
Post-stage 2 LOS, d  SD 13.4  23.0 12.4  11.9 .55
Neurodevelopmental evaluation
Weight at 14 mo, kg  SD 9.22  1.31 9.38  1.28 .27
Height at 14 mo, cm  SD 74.7  3.76 75.2  4.13 .20
Head circumference at 14 mo, cm  SD 45.9  1.98 45.7  2.09 .46
Serious adverse events until 14 mo, n  SD 0.71  1.38 0.47  0.89 .028
MDI score at 14 mo  SD 90.6  16.2 90.6  17.3 .98
PDI score at 14 mo  SD 76.9  19.2 73.8  18.7 .12
SD, Standard deviation; GED, General Educational Development; DHCA, deep hypothermic circulatory arrest; LOS, length of stay; MDI, Mental Development Index;
PDI, Psychomotor Development Index; APOE, apolipoprotein E. *Information on maternal education collected on 119 patients in the incomplete data subset.
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Dreason for missing data was lack of APOE genotype. The
only significant differences in patient andmanagement vari-
ables between patients with complete versus incomplete
data were a greater proportion of Hispanic patients and a
greater frequency of serious events in the group with com-
plete data (Table 1). Overall, the cohort with complete data
was predominately male (65%) and white (65%), very
similar to the composition of the initial discovery cohort.5,17
The predominant diagnosis was HLHS (77%). The ε2 alleleThe Journal of Thoracic and Carwas present in 11% of the cohort. APOE genotype was in
Hardy-Weinberg equilibrium, with a rejection cutoff of
P<104. For the entire cohort, the median PDI was 76.9
(range, 50-120) and the median MDI was 90.6 (range,
50-132).
In the overall cohort, after adjustment for preoperative
and postoperative covariates, the APOE ε2 allele was asso-
ciated with a lower PDI score (P ¼ .038). Other significant
predictors of the PDI score were study center, height at thediovascular Surgery c Volume 148, Number 6 2563
TABLE 2. Stepwise regression results for Bayley-II PDI score at 14
months of age (n ¼ 298)
Variable
Beta
coefficient ± SE
% PDI
explained
P
value
Site — 10.87 .00037
Height at 14 mo (cm) 1.27  0.303 8.46 3.28 3 105
Post-Norwood LOS (d) 0.137  0.0394 5.34 .00062
Presence of genetic syndrome 7.09  2.54 1.93 .0057
Pre-stage 2 surgery head
circumference (cm)
1.068  0.458 1.18 .021
APOE ε2 genotype 6.50  3.11 1.04 .038
Number of serious adverse
events
1.70  0.972 0.89 .081
Gender (female) 2.98  2.14 0.49 .16
SE, Standard error; PDI, Psychomotor Development Index; LOS, length of stay;
APOE, apolipoprotein E.
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Dtime of ND evaluation, postoperative LOS during the Nor-
wood hospitalization or neonatal palliation, presence of a
genetic syndrome, head circumference at the time of stage
2 surgery, and the number of serious adverse events up to
the neurodevelopmental evaluation (Table 2). The overall
model explained 24.9% of the variability in the PDI scores.
After removing the syndromic patients (n¼ 66), the associ-
ation of the APOE ε2 allele with the PDI score became less
significant (P ¼ .06). After covariate adjustment, patients
with the APOE ε2 allele would be predicted to have a PDI
score that was approximately 6 points lower than those
without the risk allele, explaining 1.04% of overall PDI
variance.
For the overall cohort, there was a marginal effect of
APOE ε2 allele on MDI scores (P ¼ .058). Significant
predictors of the MDI score were study center, birth weight,
postoperative LOS during the stage 2 hospitalization,
presence of a genetic syndrome, race other than white,
female gender, and head circumference at the time of NDTABLE 3. Stepwise regression results for Bayley-II MDI score at 14
months of age (n ¼ 298)
Variable
Beta
coefficient ± SE
%MDI
explained
P
value
Site — 15.46 1.18 3 107
Post-Norwood LOS (d) 0.0955  0.0391 7.83 .015
Birth weight (g) 0.00623  0.00172 4.19 .00035
Presence of genetic
syndrome
6.35  2.20 2.58 .0043
Post-stage 2 LOS (d) 0.215  0.0815 1.79 .0909
Race other 16.41  5.46 1.70 .0029
Gender (female) 5.15  1.89 1.09 .0068
Head circumference
at 14 mo (cm)
0.966  0.485 0.83 .048
APOE ε2 genotype 5.15  2.70 0.84 .058
Maternal education 0.965  0.686 0.46 .14
SE, Standard error; MDI, Mental Development Index; LOS, length of stay; APOE,
apolipoprotein E.
2564 The Journal of Thoracic and Cardiovascular Surevaluation (Table 3). The overall model explained 31.4%
of the variability in the MDI scores. After removing the
syndromic patients (n ¼ 66), the association of the APOE
ε2 allele with the MDI score became more significant
(P ¼ .02). The presence of the APOE ε2 allele accounted
for 0.84% of overall MDI variation. After covariate adjust-
ment, nonsyndromic patients with the APOE ε2 allele
would be predicted to have a MDI score that was approxi-
mately 7 points lower than those without the risk allele.
DISCUSSION
These findings validate the previously reported associa-
tion of the APOE ε2 allele with early ND disability after
cardiac surgery in neonates and infants.5,10 There are
multiple reports of genotype-phenotype associations in
many populations that have failed replication in indepen-
dent studies.17-19 To our knowledge, this represents the
first time that a genotype-phenotype association modifying
postoperative outcomes after surgery for CHD has
been replicated in an independent cohort. Replication of
the initial finding is necessary to establish the validity
of a genotype-phenotype association.17-19 The impact of
APOE genotype on an individual patient’s ND outcomes
is significant. After adjustment for covariates, patients
with the ε2 allele are predicted to have PDI and MDI
scores 6 to 7 points lower than those without the risk
allele, similar to the magnitude of the effect in the
discovery cohort.5 This is a significant decline and repre-
sents more than a 1/3 standard deviation decrease in the
scores. However, APOE genotype explained only approxi-
mately 1% of the variation in MDI and PDI scores in the
overall cohort, which is less than the variation explained
by other factors such as site, postoperative LOS, growth,
and presence of genetic syndromes. The small overall
impact likely relates to the relatively low frequency of
APOE ε2, which was present in only 11% of the cohort.
ApoE-containing lipoproteins are the primary lipid trans-
port vehicles in the CNS and have an important role in
mobilization and redistribution of cholesterol and phospho-
lipids during remodeling of neuronal membranes.9 The
gene for the human APOE is located on chromosome 19
and codes for a 299 amino acid protein. There is increasing
evidence that ApoE protein is important for neuronal repair.
There are 3 common isoforms of ApoE protein (E2, E3, and
E4), which are encoded by 3 alleles (ε2, ε3, and ε4, respec-
tively) and vary by single amino acid substitutions at 2 sites.
The normal function of ApoE within neurons is believed to
be maintenance of microtubular integrity and stabilization
of the neuronal cytoskeleton.9,20 Mechanisms by which
ApoE may modify CNS injury include protection against
oxidative stress, modulation of the glial response to
inflammation, and a direct neurotropic effect on injured
neurons. ApoE synthesis is upregulated by astrocytes and
oligodendrocytes after CNS injury or cerebral ischemia.gery c December 2014
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DStudies in APOE knockout mice have shown that ApoE
deficiency worsens neuronal injury after cerebral ischemia
and compromises the blood-brain barrier after CNS
injury.9,20,21 A recent study using brain biopsies from
patients with epilepsy found that neurons from patients
with the APOE ε4 allele are less resilient to the chronic
excitation of epilepsy.22 Neurons from patients with
APOE ε3ε3 demonstrated more beneficial responses to hy-
perexcitability, neuroinflammation, and neuronal DNA
damage. APOE genotype may also modulate white matter
development. Westlye and colleagues23 evaluated white
matter microstructure in healthy adults. Carriers of either
the ε2 or ε4 allele demonstrated regional decreases in frac-
tional anisotropy. This finding, and the known role of ApoE
in cholesterol transport, support a functional role for APOE
in myelin-related processes in the brain. Trachtenberg and
colleagues24 assessed functional connectivity in cognitively
normal adults using functional magnetic resonance imaging
and found different patterns of connectivity based on APOE
genotype. They speculate that APOE genotype has an
intrinsic effect on the development and differentiation of
functional networks in the brain.
In adults, strong associations have been validated
between the APOE genotype and Alzheimer disease, as
well as recovery after traumatic brain injury (TBI).20,25,26
In adults, the APOE ε4 allele is associated with an
increased risk of Alzheimer disease and worse recovery
after TBI. However, multiple studies have demonstrated
that the effects of APOE genotype on recovery after brain
injury are not the same in the immature developing brain
as in the aging brain. In contrast to adults, the ε2 allele is
associated with worse outcomes and the ε4 allele is
protective after a variety of types of brain injury in
infants and children. APOE genotype has been shown to
modify the adverse effects of lead exposure in children.
In a study of lead exposure by Wright and colleagues,27
the APOE ε4 allele was associated with a 4.4 point higher
score on the MDI. The negative effects of lead exposure on
the MDI were 4-fold greater for ε2 and ε3 carriers
compared with ε4 carriers. Chronic diarrhea with malnutri-
tion is associated with deficits in cognition and executive
function.28-30 In children who have multiple diarrheal
episodes early in life, the ε4 allele is associated with
better visual working memory and semantic fluency.
However, Gelfand and colleagues31 found that the ε4 allele
is associated with an increased risk of perinatal arterial
ischemic stroke. In addition, the data on the impact of
APOE genotype on the risk of cerebral palsy (CP) is mixed.
Braga and colleagues32 reported a higher prevalence of
APOE ε2 carriers in patients with CP and, in a study by
Kuroda and colleagues,33 APOE ε2 carriers had a 12-fold
increased risk of CP and ε4 carriers a 5-fold increase. Wu
and colleagues34 also described an increased prevalence
of the APOE ε4 allele in patients with CP; however, theThe Journal of Thoracic and Carassociation was not significant after correction for multiple
comparisons. A recent study from Australia which
evaluated 35 candidate genes and the risk of CP found no
association between APOE genotype and CP.35
There are limitations to this study. Because this is a
secondary analysis, data including APOE genotype, are
incomplete for some patients. Nonetheless, our study has
important strengths, which are necessary for validation of
a genotype-phenotype association. Our validation cohort
population was similar to the discovery cohort, had similar
environmental exposures, and the same phenotype was
assessed using the same instrument. Specifically, both the
discovery and validation cohorts consist of neonates and
infants with CHD undergoing surgery with CPB early in
life. The ethnic makeup of the 2 cohorts is similar, reducing
the risk of population stratification altering the results. Both
the discovery and validation studies assessed the phenotype
of early ND outcomes using the BSID-II, and the magnitude
of the effect of the APOE ε2 allele on PDI and MDI scores
was similar in both cohorts.
In summary, this study provides evidence confirming the
previous report that the APOE ε2 allele is associated with
worse early ND outcomes after cardiac surgery in neonates
and infants. This APOE genotype–environment interaction
demonstrates that genetic variants that impair neuroresilience
and CNS recovery may explain some of the interindividual
variation in developmental outcome after surgery for CHD.
However, it would be premature to begin routine clinical
testing of APOE genotype, as the impact is small and the
knowledge would not alter clinical management. These find-
ings support the need for studies to delineate the mechanisms
by which APOE genotype modulates brain recovery and
investigate potential therapies. Future studies of neurologic
outcome and clinical trials of new neuroprotective strategies
should include risk stratification for APOE genotype. In
addition, further studies are needed to identify other genetic
variants thatmodify the risk of brain injury andNDdisability.
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Discussion
Dr Charles D. Fraser (Houston, Tex). I would really like to
congratulate Dr Gaynor and colleagues for yet another important
contribution to the search for understanding of the complexities
of abnormal neurodevelopmental outcomes in children requiring
cardiac surgery. This study presented on behalf of the Pediatric
Heart Network Infant Single Ventricle Trial and the Single
Ventricle Reconstruction Trial investigators sought to validate
work that Dr Gaynor has previously conducted in a group of
newborn infants with varying cardiac diagnoses in which the
Apo-lipoprotein E E2 allele was associated with poorer
neurodevelopmental outcomes as determined in 224 infants using
the Bayley II Scale of Infant Development (BSID) evaluated by
the Psychomotor Developmental Index (PDI) and the Mental
Developmental Index (MDI).
The present study focuses on single-ventricle patients,
predominantly children with hypoplastic left heart syndrome
who survived to undergo the BSID evaluation at 14 months of
life and whose APOE genotype had been assessed; from the initial
combined cohort of 713 individuals; 298 patients were eligible for
this study. And as Dr Gaynor has so elegantly presented, important
findings include a median PDI of 76.9, normal being 100, and a
median MDI of 90.6, also normal being 100.
For the entire cohort, the APOE E2 allele was associated with a
statistically significant lower PDI score and a lower MDI score
approaching significance. Then after removing clearly syndromic
patients from the analysis, both PDI and MDI scores were
significantly lower in children with the E2 allele. Of note, and
part of my questioning below, the E2 allele was calculated to
explain roughly 1% of the overall PDI and MDI variance, but
the site of the surgery was most strongly associated with the
observed variation accounting for between 10% and 15% of the
variation.
So my questions are:
(1) Given these results, can genotyping for the E2 allele now be
added to our armamentarium in counseling families about neuro-
developmental risk in their newborn infants facing cardiac sur-
gery? And can this be extended into fetal life or should it be?
Dr Gaynor. Again, I think it is hard to know until we can actu-
ally do something about it. When we actually set up our original
study, the Institutional Review Board told us we could not tell
the families what gene we were testing or what the result was,
because they were concerned that the epsilon 4 allele is the 1 asso-
ciated with the risk of Alzheimer disease and they were concerned
that we would be giving them news that would make them worry
that we could do nothing about.
I think for clinical trials, yes, it is going to be something that will
help us understand the variation. If we develop a therapeutic strat-gery c December 2014
Gaynor et al Congenital Heart Disease
C
H
Degy that can be based on the genotype, then it should definitely be
incorporated into it. I do not think I would recommend it for
routine care until we have a therapy based on it.
Dr Fraser. I do not want to dominate the discussion, but I have
to have a corollary to that question though. So you are going to
publish this and there are going to be parents who are going to
find out this information and they are going to ask you, ‘‘Should
my child have a genotype for this?’’ The answer would be ‘‘No’’?
Dr Gaynor. I would tell them right now there is nothing we can
do at the current time to change our therapy based on this
genotype.
Dr Fraser. Question 2: you note the increasing evidence that
APOE protein is important for neuronal repair and patients with
abnormal APOE genotype are more susceptible to oxidative
stress-related neuronal injury; is it not logical to conclude that
perioperative strategies that mitigate the potential for neuronal
injury should have benefit as modifiable risk factors for neurode-
velopmental outcome because at present we are unable to modify
the genotype?
Dr Gaynor. If we could find a strategy that might mitigate the
risk, that would make sense. Currently, the best evidence we have
is based on neural imaging techniques and early neurodevelop-
mental outcomes. Of all the strategies, continuous bypass, ante-
grade cerebral perfusion, deep hypothermic circulatory arrest, all
are associated with somewhere between a 30% and 40% incidence
of new injury based on early magnetic resonance imaging. That is
from our institution, your institution, multiple other institutions.
In a recent large study from New Zealand, they looked at the
risk of new injury and neurodevelopmental outcomes, and the
degree of brain immaturity at the time of surgery was a more
important predictor than the operative management strategies. In
the SVR trial where patients were managed with both deep hypo-
thermic circulatory arrest and antegrade cerebral perfusion, we
could not identify a difference.
If we could identify an operative management strategy that we
could show, then yes, it might make a difference. When we looked
at different groups in our own cohort, we could not identify any
difference in the effect whether or not they had circulatory arrest
or continuous bypass.
Dr Fraser.Well, that is a good segue into my last question, and
particularly provocative given the data that Dr Karamlou presented
earlier. I find it fascinating and to my view the most important
point of your study, frankly, that the strongest association is with
the site of surgery. As per the above, given your previous work
focusing on nonmodifiable risk factors, are you ready to update
your viewpoint on the complex interplay of modifiable and
nonmodifiable causes of injury?
To my reading of this study, although the E2 allele is associated
with some significant level of increased susceptibility, the location
of the child’s surgery has a much stronger influence. My interpre-
tation is that certain centers through the complex interplay of
modifiable perioperative factors (surgery, perioperative care,
cardiopulmonary bypass, and others unknown) are able to achieve
better results in terms of brain protection and we do not fully
understand why.
Dr Gaynor. I would agree. In the SVR paper we struggled with
this. There are several potential things. We do not know if there
are unmeasured differences in the patient populations betweenThe Journal of Thoracic and Carthe centers. To the best we could ascertain, the groups were
similar.
There are clearly differences in operative strategies between the
centers, but what we could measure in terms of bypass manage-
ment, blood gas management, other things like that, none of those
came out.
One of the other things that we did find and we were concerned
about is that there may be some ascertainment by us between cen-
ters. There were some centers where it looked like there was a drift
of scores over time, that the scores either got higher or lower over
time. One of the flaws of the SVR strategy was that we did not have
a retest of the evaluators for the Bayley scales. So there are a
variety of reasons. There may be unmeasured factors. Everything
that we looked at between the centers in terms of patient character-
istics, operative management strategies, we could not identify a
difference. We even did a subgroup analysis looking at Michigan,
Wisconsin, CHOP, and Boston, which have very different strate-
gies, and could not identify any difference in outcomes between
those centers. So we tried to look at that to see if we could identify
either a patient factor or a management strategy that would explain
that, and we are still not sure and there is this lingering concern that
some of it may be due to ascertainment bias.
Dr Fraser. Well, I just have to push on that a little bit. I could
get it if it were a few-fold difference, but it is a 15-fold difference.
Dr Gaynor. I agree. The measured factors that we looked at,
and there may be other factors that we did not, but in the subgroup
analysis of the 4 largest centers contributing, we could not identify
any real difference in outcomes. And where we could look to make
sure the populations were the same and any impact of management
strategies, we could not identify that. That leaves open, there is a
hypothesis, there may be some differences; however, when you
look again from your center, our center, neuroimaging, very
different strategies, and yet we have very similar outcomes. I think
it is an important question, but I do not think we have answered
that yet.
Dr Hillel Laks (Los Angeles, Calif). It was a great paper. Is
there any evidence for this APOE E2 allele, or in patients without
that, that the age at which you are exposed to bypass or circula-
tory arrest makes a difference? In this particular analysis did the
time of surgery with regard to the maturity of the brain make a
difference?
Dr Gaynor. We included age at surgery as 1 of the covariates
and it did not come out.
Dr Laks. And do you have data in terms of the maturity of the
brain; when is the inflection point at which it might be safer to use
these techniques and bypass?
Dr Gaynor. Well, it is hard to know. Based on early postnatal
imaging before surgery, there is about a 4- to 5-week immaturity
of the brain. If you think, we have a baby who is 37 or 38 weeks,
their brain is probably something more along 32 to 33 weeks.
There probably is a population of vulnerable white matter precur-
sors at that point. And we know brain maturation is delayed in
these kids. It suggests you would have to wait 5 to 6 weeks to allow
the brain to come to a normal maturity.
Now, that is problematic in itself. Youmay have to keep the child
in the ICU on prostaglandins. We have some data that was just pre-
sented at the American Heart Association that suggests delaying
stage 1 past about 5 days of life increases the risk of white matterdiovascular Surgery c Volume 148, Number 6 2567
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Dinjury. So I think it is a complex interplay. If they did not require
neonatal surgery or did not have ductal-dependent pulmonary or
systemic blood flow, it might be possible to delay until they are
out of the neonatal period and the brain ismatured.Butmany of these
kids are ductal dependent for either systemic or pulmonary blood
flow.
Dr Laks. But you could argue that an off-pump procedure,
which would get a similar result, would be better if you could delay
the open procedure for at least 5 weeks.
Dr Gaynor. It might be. But again, if you do a shunt off pump,
you may introduce a steal. If you do the hybrid procedure for stage
1, there is concern that then cerebral blood flow is retrograde, up aEDITORIAL CO
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factors, and I do not think the study has been done that would allow
us to answer that question.
Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). I just have 1
other question for you. This gets back to what Chuck Fraser
brought up about the variation across sites. If you looked at the
mortality across those sites, was that associated with worse
neurodevelopmental outcomes at long-term follow-up?
Dr Gaynor. We tried to look at that thinking there might be a
survivor bias, that some sites could get sicker kids through and
they would have worse outcomes, and we could not identify
anything like that.MMENTARYValidation accepted, but look at what else was revealedErle H. Austin III, MDCardiac surgery for neonates and infants has evolved sub-
stantially in the past several decades with significant
improvement in survival for all forms of congenital heart
disease. Survival, of course, is only the first objective. Par-
ents want their child to survive, but they also want their
child to thrive after recovering from heart surgery. Those
of us who care for these patients are paying an increasing
amount of attention to neurodevelopmental outcomes.
One of several areas directed at improving neurodevelop-
mental outcomes is the identification of genetic markers
that correlate with neurologic outcome. In 2003, Gaynor
and colleagues1 demonstrated a significant detrimental
effect of the apolipoprotein E (APOE) ε2 allele on the neu-
rodevelopmental outcome of patients aged 6 months or less
who had undergone cardiac surgery. In this single-center
prospective study, neurodevelopmental evaluation was per-
formed using the Bayley Scales of Infant Development
assessed at 12 months of age. The presence of the ε2 allele
correlated with a 7-point decrease in the Psychomotor
Developmental Index (PDI) compared with patients withoutthat allele. As the apolipoprotein E protein is considered an
important factor in repairing injured neural tissue, the pres-
ence of the ε2 allele in these patients is believed to adversely
affect the ability of the protein to perform such repair after
neonatal and infant heart surgery.
As the authors of the accompanying report2 indicate,
reports of genotype-phenotype associations are rarely vali-
dated. The initial report was the product of much work and
many resources at a center with a substantial volume of
patients. Repeating that process for the sake of validation
was unlikely. Fortunately, it was recognized that the Pediat-
ric Heart Network had been independently studying similar
patients in 2 multicenter trials (the Infant Single Ventricle
[ISV] and the Single Ventricle Reconstruction [SVR] tri-
als). Fortunately, APOE testing had been performed on
the SVR patients and DNA had been extracted from blood
samples of the ISV patients. Furthermore, in both trials,
neurodevelopmental testing (Bayley Scales of Infant
Development-II [BSID-II]) had been performed on most
patients. Thus, the opportunity to validate or refute the find-
ings of the initial report presented itself.
After appropriate selection of patients, the authors of the
current report identified 298 patients with complete APOE
and neurodevelopmental data. The presence of the ε2 allele
imparted a 6-point decrease in PDI score, almost the same
as the 7-point decrement in PDI determined in the primary
report. A decrement in the Mental Developmental Index
(MDI), the other portion of BSID-II, was also seen at a level
just short of significance, but again, similar to what was
found in the initial study. I think it is fair to say this
genotype-phenotype association has been validated. The
authors are to be congratulated for identifying thisgery c December 2014
